Defining the optimal approach to the patient with postradiation prostate‐specific antigen recurrence using outcome data from a prospective randomized trial

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|119|18|3280-3286

ISSN： 0008-543x

Source： CANCER, Vol.119, Iss.18, 2013-09, pp. : 3280-3286

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Impacts of Antibiotic and Anti-Inflammatory Therapies on Serum Prostate-Specific Antigen Levels in the Presence of Prostatic Inflammation: A Prospective Randomized Controlled Trial

By  

Urologia Internationalis, Vol. 84, Iss. 2, 2010-03 ,pp. : 185-190

Karger

Access to resources Recommend Favorite

The Prostate Cancer Prevention Trial risk calculator and the relationship between prostate‐specific antigen and biopsy outcome

By  

CANCER, Vol. 119, Iss. 16, 2013-08 ,pp. : 3007-3011

John Wiley & Sons Inc

Access to resources Recommend Favorite

The prostate-specific antigen test

By Roobol Monique J  

Expert Opinion on Medical Diagnostics, Vol. 7, Iss. 5, 2013-09 ,pp. : 423-426

Informa Healthcare

Access to resources Recommend Favorite

Editorial Comment from Dr Mearini to Postoperative prostate‐specific antigen monitoring interval for radical prostatectomy patients with low recurrence risk

By  

INTERNATIONAL JOURNAL OF UROLOGY, Vol. 22, Iss. 9, 2015-09 ,pp. : 885-885

John Wiley & Sons Inc

Access to resources Recommend Favorite

Editorial Comment from Dr Schiavina and Dr Borghesi to Postoperative prostate‐specific antigen monitoring interval for radical prostatectomy patients with low recurrence risk

By  

INTERNATIONAL JOURNAL OF UROLOGY, Vol. 22, Iss. 9, 2015-09 ,pp. : 886-886

John Wiley & Sons Inc

Access to resources Recommend Favorite